Table 2 Patient demographics and baseline characteristics at study entry (parent study safety population)
3001 ApoE ε4 carrier study | 3000 ApoE ε4 noncarrier study | ||||
|---|---|---|---|---|---|
PBO (n = 215) | BAP 0.5 (n = 275) | PBO (n = 76) | BAP 0.5 (n = 66) | BAP 1.0 (n = 56) | |
Mean age (years) | 69.8 | 70.6 | 67.3 | 69.8 | 68.9 |
Femalea (%) | 62.3 | 67.6 | 61.8 | 53.0 | 62.5 |
Whitea (%) | 80.9 | 75.3 | 78.9 | 74.2 | 66.1 |
Asian (%) | 18.1 | 22.9 | 21.1 | 25.8 | 32.1 |
Mean duration of AD (years) | 2.89 | 2.98 | 2.73 | 2.85 | 2.87 |
Mean baseline MMSE | 21.3 | 21.4 | 20.2 | 20.8 | 20.6 |
Current AChEI and/or memantine use, n (%) | |||||
Yes | 199 (92.6) | 255 (92.7) | 70 (92.1) | 56 (84.8) | 54 (96.4) |
No | 16 (7.4) | 20 (7.3) | 6 (7.9) | 10 (15.2) | 2 (3.6) |
ApoE ε4 allele count, n (%) | |||||
1 | 171 (79.5) | 217 (78.9) | NA | NA | NA |
2 | 44 (20.5) | 58 (21.1) | NA | NA | NA |